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ABSTRACT
Introduction Our objective was to compare high- 
sensitivity C- reactive protein (hsCRP) levels in children 
with type 1 diabetes, healthy controls, and children with 
obesity. Additionally, we aimed to analyze the association 
between hsCRP levels and glycemic control measured 
by glycohemoglobin A (HbA1c) and anthropometric and 
biochemical variables.
Research design and methods We conducted a non- 
randomized descriptive study of children with type 1 
diabetes matched for sex and age with a control group 
and group with obesity. We recorded anthropometric 
parameters and studied variables related to diabetes, blood 
pressure, lipid profile, and HbA1c. hsCRP was measured 
by ELISA.
Results We included 49 children with type 1 diabetes, 
46 controls, and 40 children with obesity. hsCRP levels 
were significantly higher in the group with type 1 diabetes 
compared with controls and nearly significantly lower than 
in the group comprising children with obesity. We found no 
correlation between hsCRP and HbA1c and characteristics 
of type 1 diabetes with the exception of albumin to 
creatinine ratio. Statistically significant association was 
found between hsCRP and body mass index (BMI) and 
waist circumference Z- score.
Conclusions The higher hsCRP levels observed in 
children with type 1 diabetes compared with a control 
group with a similar BMI suggest a basal inflammatory 
state that could increase cardiovascular risk. The main 
factors related to hsCRP are BMI and waist circumference, 
so obesity prevention should be a priority when performing 
follow- up in children with type 1 diabetes.
INTRODUCTION
Although cardiovascular disease (CVD) has 
been traditionally linked to type 2 diabetes, it 
is also the most important cause of morbidity 
and mortality among patients with type 1 
diabetes.1 Data from large epidemiologic 
studies worldwide indicate that the incidence 
of type 1 diabetes has been increasing by 
2%–5% worldwide,2 and coronary disease is 
2–10 times more prevalent among patients 
with type 1 diabetes compared with non- 
diabetic subjects.3
Some reports conclude that glycemic 
control measures obtained using glycosylated 
hemoglobin A1c (HbA1c) could point to 
a primary risk factor for atherosclerosis in 
type 1 diabetes.4 5 However, even though the 
Diabetes Control and Complications Trial 
found that higher levels of HbA1c were asso-
ciated with microvascular and macrovascular 
complications, hyperglycemia does not fully 
explain the elevated risk of CVD.5 6 Data on the 
Significance of this study
What is already known about this subject?
 ► It is known that children with type 1 diabetes are 
more at risk of developing cardiovascular disease 
compared with non- diabetic subjects. Furthermore, 
high- sensitivity C- reactive protein (hsCRP) is a well- 
known independent inflammation marker involved in 
the pathogenesis of atherosclerosis.
What are the new findings?
 ► This is one of the first studies to simultaneously an-
alyze hsCRP values in children with type 1 diabetes 
compared with a control group and children with 
obesity. Our findings indicate that circulating levels 
of hsCRP were significantly higher in children diag-
nosed with type 1 diabetes than in healthy control 
children. The main factors related to hsCRP are body 
mass index and waist circumference, but the HbA1c 
is not related to hsCRP. In our study the mean age 
is lower than previous reports and includes patients 
with shorter duration of diabetes disease, which 
confers more relevance on a high inflammation 
grade from earliest stage of disease.
How might these results change the focus of 
research or clinical practice?
 ► It is necessary to investigate the potential relation-
ship with other potential markers of disease control. 
Considering the existence of an inflammatory state 
since early childhood, we should monitor inflam-
matory parameters in type 1 diabetes children that 
would allow to determine the highest risk patients to 
prevent the cardiovascular disease in these patients.
 on A











are: first published as 10.1136/bm




2 BMJ Open Diab Res Care 2020;8:e001424. doi:10.1136/bmjdrc-2020-001424
Cardiovascular and Metabolic Risk
relationship between HbA1c and cardiovascular compli-
cations are weak, as large clinical trials and epidemiolog-
ical cohort studies in adults have had conflicting results. 
In addition, long- term studies in children are lacking.3 As 
a result, the study of additional markers that could play a 
role in the elevated cardiovascular risk and in the inflam-
matory process and endothelial dysfunction observed in 
early childhood merits further investigation.4 6 Moreover, 
recent studies have demonstrated a relationship between 
acute hypoglycemia and indexes of systemic inflamma-
tion.1 7 These studies suggest that hyperglycemia as well 
as acute hypoglycemia produces complex vascular effects 
involved in the activation of proinflammatory mecha-
nisms in type 1 diabetes.1 3
High- sensitivity C- reactive protein (hsCRP) is a well- 
known independent inflammation marker involved 
in the pathogenesis of atherosclerosis. This protein is 
increased in patients with coronary artery disease.6 8 
Furthermore, because of its precision, accuracy, and stan-
dardization, hsCRP is considered one of the best inflam-
mation markers in clinical practice.9
Changes in weight can modify hsCRP concentrations 
in children with type 1 diabetes, and these changes have 
important implications for clinical practice.4 hsCRP is 
considered an important link between atherosclerosis, 
CVD, and insulin resistance.8 10 Several studies have iden-
tified higher levels of hsCRP as a risk factor for cardiovas-
cular events in children with obesity,11 adults with type 
1 and type 2 diabetes,8 12–14 and for the progression of 
diabetes complications.15 16
Despite this evidence, hsCRP has been poorly studied 
in children with type 1 diabetes. In addition, most 
studies in adults have included patients with potentially 
confounding factors such as hypertension, dyslipidemia, 
obesity, smoking, and diabetes complications, and as a 
result the extent to which hsCRP is associated with CVD 
risk factors in children and adolescents has yet to be 
elucidated.1 8
Taking into account the scarce data available on hsCRP 
in the pediatric population with type 1 diabetes, our 
main objective in this study is to compare hsCRP levels in 
children with type 1 diabetes against a control group of 
healthy children and another group made up of children 
with obesity. In designing this study, we hypothesized that 
HbA1c, as marker of metabolic control of type 1 diabetes, 
would be related to hsCRP levels.
METHODS
Type of study
This descriptive study was conducted between January 
2018 and November 2019 in the pediatric endocrinology 
unit of Fundación Jiménez Díaz Hospital, located in 
Madrid, Spain.
Sample size calculation
To obtain hsCRP values in patients with type 1 diabetes 
that were at least twice as high as those of an age and 
sex- matched control group with an estimated hsCRP 
value of 0.7 mg/L (standard deviation score (SDS) of 
1.2),11 a minimum of 33 subjects in each group is needed 
to achieve a statistical power (β) of 90% and level of 
significance α of 0.05.
Subjects
A. Group with type 1 diabetes: children between 6 and 
18 years of age diagnosed with type 1 diabetes accord-
ing to the criteria published by the American Diabe-
tes Association,17 with confirmed positive pancreatic 
autoimmunity (ICAS, anti- GAD, and/or anti IA-2). 
We ruled out patients who presented another chron-
ic disease or complications of diabetes, including re-
nal impairment (no evidence of microalbuminuria at 
baseline), retinopathy, neuropathy, and cardiac dys-
functions.
B. Control group: healthy children with a body mass in-
dex (BMI) of between –1.5 and +1.5 SDS relative to 
the mean according to reference charts paired with 
an age and sex- matched group with type 1 diabetes.18
C. Group with obesity: children with a BMI of more than 
2 SDS over the mean according to reference charts 
and no other chronic disease, matched with the group 
with type 1 diabetes mellitus (DM1) by age and sex.18
In these three groups, patients with levels of hsCRP >10 
mg/L were removed from analysis since higher levels of 
hsCRP are considered a marker of an infection or inflam-
matory process in accordance with American Heart Asso-
ciation guidelines.19
Measures
Clinical and demographic variables
Age, sex, BMI (kg/m2 and Z- score),18 waist circumfer-
ence (cm and Z- score),20 blood pressure (mm Hg and 
Z- score),21 Tanner stage.22 23
Specific clinical and demographic variables per group
Group with type 1 diabetes: age at diabetes diagnosis, 
presence of ketoacidosis at onset, duration of diabetes, 
insulin regimen (multiple doses or continuous subcuta-
neous insulin infusion), total daily insulin requirement, 
urine albumin to creatinine ratio (ACR), and change in 
HbA1c over the previous year.
Biochemical data
Blood samples were obtained by venipuncture in the 
morning on hospital premises after a 12 hours’ fasting 
period. Samples were kept on ice and sent to the labora-
tory for analysis. Once centrifuged, fractions were sepa-
rated and frozen at −70°C for future analyses.
Capillary whole blood via finger- prick was collected to 
measure HbA1c using monoclonal antibody agglutina-
tion reaction, DCA Vantage.
ACR was determined in second morning urine sample.
Serum hsCRP was measured with commercial ELISA 
from Aviscera Bioscience (CRP High Sensitivity SK00080-
02) according to the manufacturer’s instructions. The 
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coefficient of variation intra- assay and interassay was 
4.2% and 9.0%, respectively.
Statistical analyses
Statistical analyses were performed using SPSS V.21.0 
(SPSS). Data are expressed as mean and 95% CIs. The 
Kolmogorov- Smirnov test was used to determine whether 
the variables under study were normally distributed. 
When possible, variables that were not normally distrib-
uted were log transformed before analysis.
Following this, and in order to evaluate the relation-
ship between hsCRP and the different variables included 
in the study, a correlation analysis was carried out. 
Subsequently, a multiple linear regression analysis was 
performed including hsCRP as the dependent variable.
Analysis of variance was used to compare mean hsCRP 
values among the three groups and to compare means 
of biochemical and anthropometric variables by hsCRP 
risk group according to the classification of the American 
Cardiovascular Association.19
P values <0.05 were considered statistically significant. 
See online supplementary file 1.
RESULTS
As seen in figure 1, the type 1 diabetes group was made 
up of 49 patients. The demographic and anthropometric 
data, as well as the biochemical variables of the three 
groups included in the study, are summarized in table 1.
As we can observe in figure 2, the mean value of hsCRP 
in the type 1 diabetes group was 2.18 mg/L (1.47–2.60), 
significantly higher than the control group (0.69 mg/L 
(0.48–0.89)) and nearly significantly lower (p=0.064) 
than the group with obesity (3.37 mg/L (2.60–4.21)).
If we exclude children with type 1 diabetes who 
presented obesity (n=2), we still observe a significant 
difference between the group with type 1 diabetes and 
the control group. Furthermore, in this case, the mean 
value in type 1 diabetes was 2.06 (1.50–2.63), significantly 
lower than the one recorded in children with obesity 
(p<0.05).
We have designed three groups according to Tanner 
stage in DM1: Tanner I (3 males/10 females), Tanner 
II–IV (12 males/2 females) and Tanner V (13 males/9 
females). We have not observed differences in hsCRP 
between these three groups: 2.17 mg/L (1.31–3.02), 
1.68 mg/L (0.32–3.04) and 2.26 mg/L (1.37–3.16), 
respectively.
We have not observed significant differences of hsCRP 
between males and females after adjusting by BMI in type 
1 diabetes group: 1.74 mg/L (1.08–2.39) vs 2.81 mg/L 
(2.05–3.58).
By dividing children with type 1 diabetes into two 
groups taking into account the median of duration of 
diabetes (<4.2 years vs ≥4.2 years), we observed signifi-
cant differences in hsCRP values: 1.42 mg/L (0.91–1.93) 
vs 2.95 mg/dL (2.07–3.83).
A correlation analysis showed a statistically significant 
correlation between hsCRP and BMI (Z- score), waist 
circumference (Z- score), and ACR (table 2). The correla-
tion between hsCRP and ACR remained significant after 
adjusting for BMI (Z- score) and waist circumference 
(Z- score). We also observed a nearly significant positive 
correlation between hsCRP and the duration of diabetes. 
We have not found a statistically significant relationship 
with lipid profile even after adjusting by Tanner stage.
Subsequently, a stepwise multivariate linear regression 
analysis was performed considering hsCRP as a depen-
dent variable and including BMI, waist circumference, 
and ACR as independent variables. The best model 
obtained included waist circumference and ACR as inde-
pendent variables and had an R2 coefficient of 32%, after 
ruling out collinearity.
Furthermore, we performed the same correlation anal-
ysis including only patients with >4 years of evolution of 
diabetes. We only found significant correlation between 
hsCRP and BMI (Z- score) (r=0.58, p<0.01) and waist 
circumference (Z- score) (r=0.64, p<0.01) . We have not 
found significant correlation between hsCRP and ACR.
To further analyze the relationship between hsCRP 
and characteristics of type 1 diabetes, children with type 
1 diabetes were divided into three groups of cardiovas-
cular risk related to hsCRP levels according to the recom-
mendation of the American Heart Association19: low risk 
(hsCRP <1 mg/L), intermediate risk (hsCRP 1–3 mg/L) 
and high risk (hsCRP >3 mg/L). We did not observe a 
significant relationship between them in the duration 
of diabetes, total doses insulin (UI/kg/day), HbA1c, 
average of HbA1c in the last 3, 6 and 12 months, systolic 
and diastolic blood pressure (Z- score) and lipid profile. 
We only found a high significant correlation between 
BMI (Z- score) and waist circumference (Z- score) in the 
group with higher hsCRP (>3 mg/L) (p<0.01).
DISCUSSION
To our knowledge, this is one of the first studies to simul-
taneously analyze hsCRP values in children with type 1 
diabetes compared with a control group and children 
with severe obesity.24 Our findings indicate that circu-
lating levels of hsCRP were significantly higher in children 
56 patients in 
follow up with
type 1 Diabetes
• 2 patients under 5 years old
• 1 patient refuse to participate
We enrolled
53 patients
• 2 patients were excluded for
presenting celiac desease 




Figure 1 Flow chart of patients with type 1 diabetes. 
hsCRP, high- sensitivity C- reactive protein.
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diagnosed with type 1 diabetes than in healthy control 
children. These data support previous studies that found 
elevated hsCRP in young subjects with DM1.4 6 25
We found a positive correlation between hsCRP values 
and waist circumference and BMI in children with type 
1 diabetes. This finding is consistent with the direct 
relationship between body weight and hsCRP in type 
1 diabetes,25 and healthy children.11 In light of these 
results, we believe that strict management of nutrition 
and physical exercise to decrease excess weight in child 
patients with type 1 diabetes has metabolic benefits (lipid 
profile, hypertension),26 and can decrease the cardiovas-
cular risk of these patients.
By including a group of age, Tanner stage and sex- 
matched children with obesity to our analysis of diabetic 
children, we observed that values of hsCRP are lower 
in children with type 1 diabetes than in children with 
obesity. In addition, the higher levels of hsCRP observed 
in type 1 diabetes compared with the control group are 
not only explained by BMI and waist circumference. In 
this regard, less than 5% of children with type 1 diabetes 
presented obesity. Furthermore, if we exclude children 
with type 1 diabetes who presented obesity (n=2), we still 
find a significant difference between values of hsCRP in 
Table 1 Anthropometric and demographic data and biochemical parameters of the control group, children with type 1 
diabetes, and children with obesity
Control group
n=46













Male/female (%) 56/44 57/43 45/55 NS
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ANOVA, analysis of variance; BMI, body mass index; HDL, high- density lipoprotein; LDL, low- density lipoprotein; NS, not significant.
Figure 2 Values of high- sensitivity C- reactive protein 
(hsCRP) in patients with type 1 diabetes, with obesity, and 
controls.
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children with type 1 diabetes, the control group, and chil-
dren with obesity. Therefore, there may be an indepen-
dent basal inflammatory state in type 1 diabetes which 
warrants further investigation.
In the present study, we have found no significant 
relationship between levels of hsCRP and HbA1c. This 
could be explained at least in part by the fact that HbA1c 
does not appear to be the best marker, as it is influenced 
by extreme values and does not provide a measure of 
glycemic variability or hypoglycemia.27 Glycemic control 
could be better evaluated by the combination of HbA1c 
and data from continuous glucose monitoring like time 
in range.27 28
We also must take into account that more intensive 
glycemic control is associated with a significant risk of 
weight gain,3 4 which may influence the levels of hsCRP. 
One study concluded that there was a significant rise in 
levels of hsCRP among intensively treated subjects who 
gained the most weight, thus suggesting a complex rela-
tionship that may be influenced by other factors.4
We have found a nearly significant relationship between 
the duration of diabetes and hsCRP in the correlation 
analysis. Moreover, we have observed a greater increase in 
hsCRP among children with type 1 diabetes with a longer 
history of the disease taking into account the median of 
duration of diabetes. In this regard, one previous study 
including adolescents described that levels of hsCRP 
increase with age.29 Nevertheless, more studies with 
higher sample size and with more data on hsCRP over 
time are necessary to clarify this relationship.
We did not observe a relationship between hsCRP and 
lipid profile in the type 1 diabetes group. Additionally, 
no difference in lipid profile was found between the 
three groups when these were analyzed by cardiovascular 
risk group. All our patients with type 1 diabetes received 
nutritional education, and in our facility we monitor the 
dietary habits of these children during outpatient visits 
held every 3 months. This could partially explain why our 
patients have a good lipid profile with no significant rela-
tionship with hsCRP. However, in the SEARCH study30 it 
was reported a positive correlation between hsCRP and 
low- density lipoprotein cholesterol and total cholesterol. 
Those differences in the results compared with our study 
could be partially explained by differences in inclusion 
criteria, sample size, race, BMI, type of diet and hsCRP 
assay.
We found a significant correlation between values 
of ACR and hsCRP despite the fact that nephropathy 
was ruled out. This finding is compatible with other 
reports that show that microalbuminuria is associated 
with a state of subclinical inflammation and endothelial 
dysfunction.29 31 32 However, how the hsCRP is related 
to microalbuminuria is not clear. Some studies suggest 
that this may be the result of inflammation rather than 
a predictive risk factor for microalbuminuria,29 while 
others hypothesize that hsCRP may play a role in the 
induction of microalbuminuria,32 suggesting that 
inflammation may deteriorate endothelial dysfunction.
A previous report showed a negative relation-
ship between testosterone and hsCRP in adolescents 
with obesity.33 Although we have not measured sex 
hormones, the lack of differences of hsCRP related to 
Tanner stage and gender in the type 1 diabetes group 
and in children with obesity (data not shown) suggests 
us that hsCRP levels seem not to be influenced by sexual 
steroids in our sample.
Our study shows some limitations. First, we used 
a single measure of hsCRP at baseline, and gathered 
no data on hsCRP over time. Another limitation is the 
absence of body composition measurements. Besides, 
data on the time in range would have been of great 
interest in patients with continuous glucose moni-
toring. Finally, we have no data of specific Tanner stage 
of the control group and we have not measured sex 
hormones.
CONCLUSIONS
The higher hsCRP levels observed in children with 
type 1 diabetes compared with a control group with a 
similar BMI and lower than children with severe obesity 
suggest a basal inflammatory state that could increase 
cardiovascular risk. However, taking into account the 
present scientific evidence, there are no enough data 
Table 2 Correlation analyses between hsCRP and 
anthropometric and demographic data and biochemical 





Age (years) 12.66 (11.57–13.74) NS
BMI (Z- score) 0.05 (−0.27 to 0.36) r=0.49 (p<0.001)
Waist circumference 
(Z- score)
0.44 (0.05–0.83) r=0.37 (p<0.001)
Duration of diabetes 
(years)
4.91 (3.93–6.01) r=0.25 (p=0.08)
TDI (UI/kg/day) 0.80 (0.74–0.86) NS
HbA1c baseline NS
  % 8.01 (7.56–8.51)
  mmol/mol 64 (59.1–69.5)
Average of HbA1c 
in the last year of 
evolution
NS
  % 8.26 (7.83–8.78)
  mmol/mol 66.8 (62.8–72.5)
ACR r=0.36 (p<0.05)
  mg/g 6.93 (4.7–9.5)
  mg/mmol 0.78 (0.53–1.07)
ACR, albumin to creatinine ratio; BMI, body mass index; HbA1c, 
glycosylated hemoglobin A1c; hsCRP, high- sensitivity C- 
reactive protein; NS, not significant; TDI, total daily insulin.
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to recommend routine test of hsCRP in the follow- up of 
children and adolescents with type 1 diabetes. In addi-
tion, further longitudinal studies are needed to study 
the evolution of these individuals until adulthood to 
evaluate the usefulness of hsCRP as a predictive cardio-
vascular biomarker.
Notably, in our patients, the main factors related to 
hsCRP are BMI and waist circumference, so weight 
control could be essential to the surveillance of patients 
with type 1 diabetes.
The HbA1c as a relevant indicator of glycemic control 
is not related to hsCRP. It is therefore necessary to 
investigate the potential relationship with other poten-
tial markers of disease control such as time in range.
Acknowledgements The authors express their gratitude to the study subjects.
Contributors PPS collected data, performed statistical analyses, and wrote 
the manuscript. OD, LH, and CVV carried out laboratory work and participated 
substantially in data analysis. IAG contributed to the collection of data and blood 
samples. CG supervised laboratory work and critically reviewed the manuscript. 
TGP and LSG designed the study, supervised data collection, verified data integrity, 
drafted some sections of the manuscript, made contributions to the interpretation 
of data, and critically reviewed the manuscript. All authors contributed to the 
interpretation of data, revised the article critically for important intellectual content, 
and approved the final version for publication.
Funding This work was supported by Fundación Familia Alonso.
Competing interests None declared.
Patient consent for publication Not required.
Ethics approval Children and parents provided assent and written informed 
consent, respectively, at the time of enrollment. The study protocol was approved 
by the Institutional Review Board of the Fundación Jiménez Díaz (code: PIC006-18, 
approval date: 27 February 2018). This investigation was carried out in adherence 
to the principles of the Declaration of Helsinki and subsequent reviews, as well as 
Spanish legislation in force on clinical research in human subjects.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement All data relevant to the study are included in the 
article or uploaded as supplementary information.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the 
use is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCID iD
Leandro Soriano- Guillén http:// orcid. org/ 0000- 0003- 4268- 8870
REFERENCES
 1 de Ferranti SD, de Boer IH, Fonseca V, et al. Type 1 diabetes 
mellitus and cardiovascular disease: a scientific statement 
from the American heart association and American diabetes 
association. Diabetes Care 2014;37:2843–63.
 2 Maahs DM, West NA, Lawrence JM, et al. Epidemiology of type 1 
diabetes. Endocrinol Metab Clin North Am 2010;39:481–97.
 3 Maahs DM, Daniels SR, de Ferranti SD, et al. Cardiovascular disease 
risk factors in youth with diabetes mellitus: a scientific statement 
from the American heart association. Circulation 2014;130:1532–58.
 4 Schaumberg DA, Glynn RJ, Jenkins AJ, et al. Effect of intensive 
glycemic control on levels of markers of inflammation in type 1 
diabetes mellitus in the diabetes control and complications trial. 
Circulation 2005;111:2446–53.
 5 Nathan DM, DCCT/EDIC Research Group. The diabetes control 
and complications trial/epidemiology of diabetes interventions 
and complications study at 30 years: overview. Diabetes Care 
2014;37:9–16.
 6 Gökşen D, Levent E, Kar S, et al. Serum adiponectin and hsCRP 
levels and non- invasive radiological methods in the early diagnosis 
of cardiovascular system complications in children and adolescents 
with type 1 diabetes mellitus. J Clin Res Pediatr Endocrinol 
2013;5:174–81.
 7 Gogitidze Joy N, Hedrington MS, Briscoe VJ, et al. Effects of acute 
hypoglycemia on inflammatory and pro- atherothrombotic biomarkers 
in individuals with type 1 diabetes and healthy individuals. Diabetes 
Care 2010;33:1529–35.
 8 Karantza MV, Mittelman SD, Dorey F, et al. Relationship of highly 
sensitive C- reactive protein and lipid levels in adolescents with type 
1 diabetes mellitus. Pediatr Diabetes 2008;9:122–6.
 9 Roberts WL. Cdc AHA workshop on markers of inflammation 
and cardiovascular disease: application to clinical and public 
health practice: laboratory tests available to asses inflammation—
performance and standardization: a background paper. Circulation 
2004;110.
 10 Timar R, Timar B, Degeratu D, et al. Metabolic syndrome, 
adiponectin and proinflammatory status in patients with type 1 
diabetes mellitus. J Int Med Res 2014;42:1131–8.
 11 Navarro P, de Dios O, Gavela- Pérez T, et al. High- Sensitivity 
C- reactive protein and leptin levels related to body mass index 
changes throughout childhood. J Pediatr 2016;178:178–82.
 12 Aburawi EH, AlKaabi J, Zoubeidi T, et al. Subclinical inflammation and 
endothelial dysfunction in young patients with diabetes: a study from 
United Arab Emirates. PLoS One 2016;11:e0159808.
 13 Balamir I, Ates I, Topcuoglu C, et al. Association of Endocan, 
Ischemia- Modified albumin, and hsCRP levels with 
endothelial dysfunction in type 2 diabetes mellitus. Angiology 
2018;69:609–16.
 14 Sahakyan K, Klein BEK, Lee KE, et al. Inflammatory and endothelial 
dysfunction markers and proteinuria in persons with type 1 diabetes 
mellitus. Eur J Endocrinol 2010;162:1101–5.
 15 Hansen TK, Forsblom C, Saraheimo M, et al. Association between 
mannose- binding lectin, high- sensitivity C- reactive protein and the 
progression of diabetic nephropathy in type 1 diabetes. Diabetologia 
2010;53:1517–24.
 16 Muni RH, Kohly RP, Lee EQ, et al. Prospective study of inflammatory 
biomarkers and risk of diabetic retinopathy in the diabetes control 
and complications trial. JAMA Ophthalmol 2013;131:514–21.
 17 American Diabetes Association. Classification and Diagnosis of 
Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes 
Care 2018;41:S13–27.
 18 Hernández M, Castellet J, Narvaíza JL, et al. Curvas Y tablas de 
crecimiento IICD (ISBN; 84-7391-177-6). Bilbao: Fundación Faustino 
Orbegozo, 1988.
 19 Ridker PM. Cardiology patient page. C- reactive protein: a simple 
test to help predict risk of heart attack and stroke. Circulation 
2003;108:e81–5.
 20 Moreno LA, Fleta J, Mur L, et al. Waist circumference values in 
Spanish children--gender related differences. Eur J Clin Nutr 
1999;53:429–33.
 21 National High Blood Pressure Education Program Working Group on 
High Blood Pressure in Children and Adolescents. The fourth report 
on the diagnosis, evaluation, and treatment of high blood pressure in 
children and adolescents. Pediatrics 2004;114:555–76.
 22 Marshall WA, Tanner JM. Variations in pattern of pubertal changes in 
girls. Arch Dis Child 1969;44:291–303.
 23 Marshall WA, Tanner JM. Variations in the pattern of pubertal 
changes in boys. Arch Dis Child 1970;45:13–23.
 24 Mangge H, Schauenstein K, Stroedter L, et al. Low grade 
inflammation in juvenile obesity and type 1 diabetes associated 
with early signs of atherosclerosis. Exp Clin Endocrinol Diabetes 
2004;112:378–82.
 25 Prado MM, Carrizo T, Abregú AV, et al. Non- HDL- cholesterol and 
C- reactive protein in children and adolescents with type 1 diabetes. 
J Pediatr Endocrinol Metab 2017;30:285–8.
 26 Downie ML, Ulrich EH, Noone DG. An update on hypertension in 
children with type 1 diabetes. Can J Diabetes 2018;42:199–204.
 27 American Diabetes Association. 6. Glycemic Targets: Standards of 
Medical Care in Diabetes-2019. Diabetes Care 2019;42:S61–70.
 28 DiMeglio LA, Acerini CL, Codner E, et al. ISPAD clinical practice 
consensus guidelines 2018: glycemic control targets and glucose 
monitoring for children, adolescents, and young adults with 
diabetes. Pediatr Diabetes 2018;19:105–14.
 29 Marcovecchio ML, Giannini C, Widmer B, et al. C- Reactive protein in 
relation to the development of microalbuminuria in type 1 diabetes: 
the Oxford regional prospective study. Diabetes Care 2008;31:974–6.
 30 Snell- Bergeon JK, West NA, Mayer- Davis EJ, et al. Inflammatory 
markers are increased in youth with type 1 diabetes: the search 
case- control study. J Clin Endocrinol Metab 2010;95:2868–76.
 on A











are: first published as 10.1136/bm




7BMJ Open Diab Res Care 2020;8:e001424. doi:10.1136/bmjdrc-2020-001424
Cardiovascular and Metabolic Risk
 31 Yan J- tao, Ye H, Wang D- wen. [The relationship between 
microalbuminuria and plasma high sensitivity C reactive protein]. 
Zhonghua Xin Xue Guan Bing Za Zhi 2005;33:534–5.
 32 Goud BKM, Nayal B, Devi OS, et al. Comparison of microalbuminuria 
with hs- CRP and low density lipoprotein levels in nondiabetic, 
nonhypertensive myocardial infarction patients. J Cardiovasc Dis 
Res 2012;3:287–9.
 33 Mogri M, Dhindsa S, Quattrin T, et al. Testosterone concentrations 
in young pubertal and post- pubertal obese males. Clin Endocrinol 
2013;78:593–9.
 on A











are: first published as 10.1136/bm
jdrc-2020-001424 on 19 July 2020. D
ow
nloaded from
 
